# Orthorebirth Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orthorebirth-co

- Industry: Medical Devices & Equipment
- Headquarters: Yokohama, Japan
- Website: www.orthorebirth.com
- Total disclosed funding: $5.3M
- Latest round: Series C (Mar 28, 2024)
- Investors on record: 1

## About

Founded in 2011 and based in Yokohama, Japan, ORTHOREBIRTH CO. LTD operates as a medical technology company that develops and offers materials used in filling bone marrow used in orthopedic surgeries. In March 2024, ORTHOREBIRTH CO. LTD raised JPY 800 million in Series C funding from SIIF Impact Capital.

ORTHOREBIRTH offers regenerative medicines such as ReBOSSIS, a synthetic bone-void-filling material made from cotton-like fibers as a replacement to natural bone. ReBOSSIS is used in orthopedic surgeries, particularly in trauma and spine fields, and is available in different versions for various markets. The company also develops Stem Cell Culture Sheets, utilizing its microfiber technology to support cell proliferation and simplify cell transfer processes. 

The company intends to use the March 2024 funding for new research and development.

## Funding rounds

- Series C, Mar 28, 2024, $5.3M — SIIF Impact Capital

## Investors

- SIIF Impact Capital (https://capitalatlas.ai/funds/siif-impact-capital) — Series C